Phil Pang: So with our 8190 antibody, which is both covering both RSV and human metapneumovirus, the answer is that we believe we can bring in IND forward in the next 12 to 24 months. And the path is relatively straightforward and has really been blazed by others where in the infant population, what you’re trying to demonstrate is prevention of lower MALRI — or lower respiratory tract infection medically attended respiratory tract infection or lower respiratory tract infection. And we believe that there’s a relatively straightforward path to do so after you obtain Phase 1 PK data. Beyond that, as you know, this is a partnered program with GSK and we are working closely with our collaborator to determine the fastest and most robust path forward. So that’s what I can say about the 8190 at this time.
Marianne De Backer: And then, Paul, on your first question, I first want to clarify that the efforts we are doing in these new areas are at discovery stage and maybe also ask Sung to provide a bit more background on how we are allocating capital here at here at Vir.
Sung Lee: So, Paul, in terms of the metrics, as Marianne said, the efforts in autoimmune and oncology would be discovery and that’s not an expensive part or doesn’t require a large investment at Vir. The capital allocation here will still largely be directed to our mid stage programs in hepatitis B and hepatitis delta. Those will be ongoing for the foreseeable future and the majority of our capital allocation will be directed there. Now, I just want to add something here. We have in the past year-to-date, our capital allocation has been heavily directed towards a couple of items. Obviously the Phase 2 flu study and the related Phase 3 manufacturing activities. Also, the liability we have to GSK related to Sotrovimab supply and manufacturing.
As you probably saw from the press release, we did take a write down for those manufacturing activities. So those costs, the flu costs are behind us now and the liabilities of GSK is effectively paid down. So again, the capital going forward will largely be directed to the clinical stage programs.
Marianne De Backer: So I would just add in addition to capital allocation to predominantly our clinical stage programs, of course, we continue to explore if there are external innovation opportunities that could help us accelerate our programs or complement what we are doing here at Vir.
Operator: Your next question comes from the line of Eric Joseph with JPMorgan.
Unidentified Analyst: It’s Billy on for Eric. Couple ones from us. First, just following up from that last question. So with the external opportunity, do you see this as something maybe for more the new immuno-oncology side or the historical virology side of the business? And then I’ll pull up my one after.
Marianne De Backer: Eric, we could not understand you very well…
Unidentified Analyst: Can you hear me now?
Marianne De Backer: Could you try again?
Unidentified Analyst: So the question was just following on from the previous question about you stated some complementary external opportunities you were looking at potentially and whether these would be more in the immuno-oncology space or in the historical space of virology?
Marianne De Backer: So as mentioned, we are looking at external innovation really from the perspective of how can we accelerate what we are already doing. I really do believe that we have world class expertise in our platforms and we want to, of course, stay at the forefront in our field. And so we are looking at anything that could help us stay there, potentially [reproc]. So that’s been both be in infectious diseases or beyond.
Unidentified Analyst: And just one quick one about the HBV program. Looking forward to the off-treatment follow up that you have now guided to in 2Q ’24. Would you expect patients to be off the NUC by that point or still on NUCs? Thanks.
